Pathologic characteristics and prognosis of a rare advanced cervical cancer treated with radical surgery and radiotherapy

Objective: To assess the prognosis of rare advanced cervical carcinoma with post-radical-radiation surgery and to compare the clinic value between further surgery treatment group and non-surgery group after radical radiation therapy. Materials and Methods: From January 2002 to July 2010 there were 68 patients with advanced stage cervical carcinoma retrospectively analysed in Maternal and Child Health Hospital of Jiangxi Province. All patients were confirmed by histopathology before treatment, and clinical staging was based on updated 2009 FIGO staging. All patients were Stage Ib2 (local advanced) and more severe. There were 36 patients (29 adenocarcinoma (AC), six adenosquamous carcinoma (ASC), and one undifferentiated carcinoma) classified into observation group that was treated with radical radiation therapy + surgery (total hysterectomy + bilateral salpingo-oophorectomy); other 32 patients (26 AC, five ASC, and one undifferentiated carcinoma) classified into control group that was treated with radical radiation therapy with no further surgery. The radical radiation therapy included external-beam radiation and intracavitary therapy, standard point A dose added up to 85 Gy (these doses are recommended for most patients based on summation of conventional external-beam fractionation and low-dose rate 40~70 cGy/h brachytherapy equivalents), and 45~55Gy was given to point B. All of the patients were followed up. The average follow-up time was 65.6 months and the survival rate between two groups were compared and analyzed whether there was residual lesion, metastasis, lymph vascular space invasion (LVSI) in the observation group. Results: In observation group there were 15 patients found positive. The positive rate was 41.7% (15/36), in which there nine cases with LVSI and residual foci, four cases with uterus invasion, and one case with only residual foci. Both of the two groups were followed up and the average follow-up time was 65.6 months (range 36~136). In observation group there were 25 cases that have survived until now and the average survival time was 66.6 months (range 36~136 ). Eleven patients died with an average survival time of 10.4 months (range 2~37). In control group there are 22 cases that survived until now (July 2013); the average survival time was 64.4 months (range 36~136 ). Ten patients died with an average survival time of 10.3 months (range 3~28 ). Three cases experienced serious complication in observation group and two cases in control group. There was no significant difference in survival time between the two groups. Conclusion: Due to low efficacy results, post-radical-radiation surgery is not a feasible treatment regimen for rare advanced cervical carcinoma.

Rare pathological type; Cervical carcinoma; Radical radiation therapy; Surgery.

[1] Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M.: “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008”. Int. J. Cancer, 2010, 127, 2893.

[2] Forman D., de Martel C., Lacey C.J.: “Global burden of human papillomavirus and related diseases”. Vaccine, 2012, 20, 5.

[3] Bray F., Carstensen B., Moller H., Zappa M., Zakelj M.P., Lawrence G., et al.: “Incidence trends of adenocarcinoma of the cervix in 13 European countries”. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 2191.

[4] Oh C.M., Jung K.W., Won Y.J.: “Trends in the incidence of in situ and invasive cervical cancer by age group and histological type in Korea from 1993 to 2009”. PLoS One, 2013, 8, e72012. doi: 10.1371/journal.pone.0072012.

[5] Missaoui N., Trabelsi A., Landolsi H., Jaidaine L., Mokni M., Korbi S., Hmissa S.: “Cervical adenocarcinoma and squamous cell carci-noma incidence trends among Tunisian women”. Asian Pac. J. Can-cer Prev., 2010, 11, 777.

[6] Mathew A., George P.S.: “Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma ofcervix—world-wide”. Asian Pac. J. Cancer Prev., 2009, 10, 645.

[7] Wabinga H.R., Nambooze S., Amulen P.M., Okello C., Mbus L., Parkin D.M.: “Trends in the incidence of cancer in Kampala, Uganda 1991-2010”. Int. J. Cancer, 2014, 135, 432. doi: 10.1002/ijc.28661. Epub 2014 Feb 27.

[8] Sherman M.E., Wang S.S., Carreon J., Devesa S.S.: “Mortality trends for cervical squamous and adenocarcinoma in the United States”. Cancer, 2005, 103, 1258.

[9] Bray F., Carstensen B., Møller H., Zappa M., Zakelj M.P., Lawrence G., et al.: “Incidence trends of adenocarcinoma of the cervix in 13 European countries”. Cancer Epidemiol. Biomark. Prev., 2005, 14, 2191.

[10] Lau K.L., Yim P.H., Cheung E.Y.: “Psychiatric morbidity in Chinese women after cervical cancer treatment in a regional gynaecology clinic”. East Asian Arch. Psychiatry, 2013, 23, 144.

[11] Chen J.L., Huang C.Y., Huang Y.S., Chen R.J., Wang C.W., Chen Y. H., et al.: “Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with de- finitive radiotherapy”. Acta Obstet. Gynecol. Scand., 2014, 93, 661. doi: 1 0.1111/aogs.12383. Epub 2014 Apr 22.

[12] Noh J.M., Park W., Kim Y.S., Kim J.Y., Kim H.J., Kim J., et al.: “Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterinecervical cancer patients re-ceiving surgical resection followed by radiotherapy: A multicenter retrospective study (KROG 13-10)”. Gynecol. Oncol., 2014, 132, 618. doi: 10.1016/ j.ygyno.2014.01.043. Epub 2014 Jan 31.

[13] Guo F., Hu Y., Xu X., Li R., Ru T., Wang J., Zhou H.: “Diagnostic challenges in minimal deviation adenocarcinoma of the uterine cervix: A report of two cases and review of the literature”. Mol. Clin. Oncol., 2013, 9, 833.

[14] Nakanishi T., Ishikawa H., Suzuki Y., Inoue T., Nakamura S., Kuzuya K.: “A comparison of prognoses of pathologic stage IB ade-nocarcinoma and squamous cell carcinomaof the uterine cervix”. Gy-necol. Oncol., 2000, 79, 289.

[15] Gao Y., Liu Z., Gao F., Chen X.: “Intraoperative radiotherapy in stage IIB adenocarcinoma of the uterine cervix: a retrospective study”. Onco. Targets Ther., 2013, 6, 1695.

[16] National Comprehensive Cancer Network: “NCCN Clinical Prac-tice Guidelines in Oncology (NCCN Guidelines): Cervical cancer. Version 3.2013. Available at http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf

[17] Shimada M., Nishimura R., Nogawa T., Hatae M., Takehara K., Ya-mada H., et al.: “Comparison of the outcome between cervical adeno-carcinoma and squamous cell carcinomapatients with adjuvant radiotherapy following radical surgery: SGSG/TGCU Intergroup Sur-veillance”. Mol. Clin. Oncol., 2013, 7, 780. Epub 2013 May 9.

[18] Shruthi P.S., Kalyani R., Kai L.J., Narayanaswamy M.: “Clinico-pathological correlation of cervical carcinoma: a tertiary hospital based study”. Asian Pac. J. Cancer Prev., 2014, 15, 1671.